Prana Biotechnology Releases Update on Phase 11a Trial of PBT2 in Alzheimer’s Patients (PBT.AX, 00745956, 20070806) (Aspect Huntley via Yahoo!7 Finance)
Prana Biotechnology announced an update on its Phase IIa clinical trial of PBT2 in patients with Alzheimer’s disease. The independent DSMB have now reviewed blinded data of over 50 patients, there have been no treatment-related serious adverse events or withdrawals and the DSMB has confirmed that the trial is safe to continue as per the original protocol. 55 patients (of the planned 80) have been …
Original post by Lyle